Table 2 Frequency and duration of reported side effects among among mothers of infants of group A (N = 45) and group B (N = 45) of an ITN trial conducted in Burkina Faso
Reported side effects | Week 1 | Week 2–4 | Week 1–18 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Frequencya | RR (95 % CI)b | P-valueb | Duration of symptom (Days) | P-valuec | Frequency | RR (95 % CI) | P-value | Duration of symptom (Days) | P-value | Frequency | RR (95 % CI) | P-value | Duration of symptom (Days) | P-value | |||||||
A | B | A | B | A | B | A | B | A | B | ||||||||||||
Headache/diziness | 11 | 2 | 6.96 (1.35–67.43) | 0.01 | 27 | 5 | 0.55 | 7 | 5 | 1.48 (0.37–6.40) | 0.76 | 44 | 13 | 0.22 | 15 | 9 | 2.00 (0.70–5.94) | 0.23 | 79 | 22 | 0.43 |
Rhinitis | 5 | 3 | 1.75 (0.31–11.94) | 0.71 | 10 | 14 | 0.39 | 5 | 7 | 0.67 (0.16–2.74) | 0.76 | 103 | 143 | 0.94 | 12 | 7 | 1.97 (0.62–6.61) | 0.30 | 71 | 49 | 0.68 |
Skin Eruption | 4 | 2 | 2.09 (0.28–24.17) | 0.68 | 19 | 7 | 0.51 | 6 | 2 | 3.31 (0.54–34.94) | 0.27 | 43 | 2 | 0.11 | 7 | 3 | 2.58 (0.54–16.38) | 0.31 | 77 | 10 | 0.15 |
Pruritus | 2 | 2 | 1.00 (0.07–14.38) | 1.00 | 7 | 7 | 1.00 | 2 | 0 | ∞ | 0.49 | 12 | 0 | – | 4 | 2 | 2.09 (0.28–24.17) | 0.68 | 24 | 8 | 0.52 |
Parestheia | 2 | 2 | 1.00 (0.07–14.38) | 1.00 | 3 | 2 | 1.00 | 2 | 0 | ∞ | 0.49 | 12 | 0 | – | 2 | 3 | 0.65 (0.05–6.01) | 1.00 | 15 | 3 | 0.22 |
Cough | 1 | 0 | ∞ | 1.00 | 1 | 0 | – | 5 | 1 | 5.50 (0.57–265.92) | 0.20 | 30 | 5 | 1.00 | 6 | 2 | 3.31 (0.54–34.94) | 0.27 | 37 | 6 | 0.75 |
Conjunctivits | 2 | 0 | ∞ | 0.49 | 2 | 0 | – | 2 | 1 | 2.05 (0.10–123.44) | 1.00 | 9 | 1 | 0.60 | 3 | 3 | 1.00 (0.13–7.90) | 1.00 | 10 | 4 | 0.24 |
Others | 8 | 5 | 1.73 (0.45–7.31) | 0.55 | 28 | 12 | 0.43 | 11 | 9 | 1.29 (0.43–4.01) | 0.80 | 64 | 42 | 0.15 | 14 | 11 | 1.40 (0.50–3.95) | 0.64 | 72 | 53 | 0.77 |